COSTA MESA, Calif., June 25 /PRNewswire-FirstCall/ -- CNS Response, Inc. today announced that its registration statement on Form SB-2 filed on May 21, 2007, with the Securities and Exchange Commission has been declared effective as of today.
The registration statement relates to the offer and sale from time to time by the stockholders named in the “Selling Shareholders” section of the registration statement of up to 7,355,199 shares of the Company’s common stock and up to 2,627,939 shares of the Company’s common stock issuable upon exercise of outstanding warrants. The prices at which the selling stockholders may sell the shares in this offering will be determined by the prevailing market price for the shares or in negotiated transactions. CNS Response will not receive any of the proceeds from the sale of the shares. The Company has borne all expenses of registration incurred in connection with this offering. The selling stockholders whose shares are being registered will bear all selling and other expenses.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Any offers of the securities will be made only by means of a prospectus.
About CNS Response
CNS Response is a life sciences company focused on the commercialization of the first patented system that guides psychiatrists in pharmacotherapy for patients with certain behavioral disorders. The Company’s system, “Referenced-EEG(SM)” or “rEEG(SM)”, matches mental and addiction patient physiology with treatment outcome (a biomarker system).
rEEG(SM) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS Response is also an aide to pharmaceutical developers, who can use rEEG(SM) to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Contacts: Investor Relations: Sara Ephraim / Stephanie Carrington (646) 536-7002 / 7017 sephraim@theruthgroup.comscarrington@theruthgroup.com Media: Janine McCargo / Jason Rando (646) 536-7033 / 7025 jmccargo@theruthgroup.comjrando@theruthgroup.com
CNS Response, Inc.
CONTACT: Investors, Sara Ephraim, +1-646-536-7002,sephraim@theruthgroup.com, or Stephanie Carrington, +1-646-536-7017,scarrington@theruthgroup.com; or Media, Janine McCargo, +1-646-536-7033,jmccargo@theruthgroup.com, or Jason Rando, +1-646-536-7025,jrando@theruthgroup.com, all for CNS Response, Inc.
